ERBB2 and breast carcinoma: At a starting does of afatinib 50 mg/day, the rate of discontinuation from the study because of AEs—particularly diarrhea—was higher than what was previously reported with reversible EGFR and EGFR/HER2 inhibitors in patients with breast cancer and may have contributed to the limited efficacy observed [28, 29].